9-[2-[4-[2-(4-Methoxyphenyl)ethyl]-3,5-dimethylpiperazin-1-yl]ethyl]carbazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-[2-[4-[2-(4-Methoxyphenyl)ethyl]-3,5-dimethylpiperazin-1-yl]ethyl]carbazole
• 化学式: C₂₉H₃₅N₃O
• 分子量: 441.6
• InChiKey: AOBCUPMYCKJVTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  20.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY AS ADJUNCTS TO OPIATES FOR PAIN
  申请人：Salvemini Daniela

  公开号：US20080241121A1

  公开（公告）日：2008-10-02

  A method for treating opiate induced tolerance or opiate induced hyperalgesia in a subject is closed. More specifically, the method provides for reducing ceramide levels with an agent thereby treating opiate induced antinociceptive/analgesic tolerance or hyperalgesia in a human or non-human subject. The method further allows for improved pain management in subjects suffering from chronic pain as well as treatment for opiate induced disorders.
• COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS
  申请人：Salvemini Daniela

  公开号：US20100086543A1

  公开（公告）日：2010-04-08

  Provided are a pharmaceutical composition and a method for reducing, preventing, or delaying the development of a biological condition associated with administration of an opioid drug, in particular, tolerance to and/or physical dependence on an opioid drug. The pharmaceutical composition includes an opioid drug, a ceramide biosynthesis inhibitor and a pharmaceutically acceptable carrier. The method of treatment involves administration of an opioid drug and a ceramide biosynthesis inhibitor. Also provided are a method of screening for an agent that reduces, prevents or delays the development of tolerance to and/or physical dependence on an opioid drug as well as compositions comprising a dsRNA for inhibiting ceramide biosynthesis in a cell and a vector for expressing a shRNA for inhibiting ceramide biosynthesis in a cell.
• Compositions and Methods for Treating Pulmonary Conditions
  申请人：Vij Neeraj

  公开号：US20130131146A1

  公开（公告）日：2013-05-23

  The present invention relates to the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary conditions. In one embodiment, a method for assessing the severity of lung damage from a pulmonary condition in a subject comprises the steps of (a) measuring the level and/or functional activity of membrane/lipid-raft cystic fibrosis transmembrane conductance regulator (CFTR)in a sample from the subject; (b) measuring the level of ceramide or its species in a sample from the subject; and (c) comparing the membrane/lipid- raft CFTR level and/or functional activity and ceramide level to a control sample, wherein a difference in membrane/lipid-raft CFTR level and/or functional activity and ceramide level is indicative of the severity of lung damage. The method can further comprise treating the subject based on the severity of lung damage. In particular embodiments, the treatment comprises administering a CFTR agonist and/or an agent that inhibits the synthesis of ccramide or its species.
• [EN] PREVENTION AND TREATMENT OF HAEMATOLOGICAL CONDITIONS<br/>[FR] PRÉVENTION ET TRAITEMENT D'AFFECTIONS HÉMATOLOGIQUES
  申请人：UNIV SYDNEY TECH

  公开号：WO2014000027A1

  公开（公告）日：2014-01-03

  The present invention relates generally to methods for the prevention and treatment of haematological conditions that exhibits elevated levels of free immunoglobulin light chains (FLCs), including multiple myeloma, B-cell lymphomas, and associated diseases and conditions.